Eli Lilly Weight-Loss Drug Outperforms Zepbound
Eli Lilly reported that its experimental combination weight-loss drug EloraTZP outperformed Zepbound in a mid-stage trial. Patients achieved significant weight loss, though discontinuation rates rose due to gastrointestinal side effects.
Xurve View
Insights:
Xurve View
ELI LILLY & CO said on Wednesday its experimental combination weight-loss drug EloraTZP outperformed Zepbound, driving an average weight reduction of 23.3% over 48 weeks in patients with diabetes. The mid-stage trial results intensify competition with NOVO NORDISK A/S-B in the global obesity market. That compared with 14.8% for patients on the highest dose of Zepbound in the same trial.
